Here we assessed the expression of genes associated with EMT in CRCs and liver metastases (LMs). Methods: Human primary CRC (n = 11) and LM (n = 21) samples
were selleck products obtained under full ethical approval from Queen’s Medical Centre, Nottingham, UK. Samples were stored in RNAlater prior to RNA extraction, cDNA synthesis, and real-time quantitative PCR to determine expression levels of EMT markers (Snail, Slug, Zeb1, E-cadherin), mesenchymal markers (vimentin, s100a4), as well as the c-Met receptor, MACC1, hepatocyte growth factor (HGF), and TGFβ1 relative to the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase. A BTK inhibitor student’s t-test was used for statistical analysis. Results: Snail (p < 0.005), vimentin (p < 0.0001), s100a4 (p < 0.005), and TGFβ1 (p < 0.005) were significantly upregulated in LMs DMXAA purchase compared to normal liver. MACC1 was significantly
uregulated in CRCs and LMs (p < 0.01), and only weakly expressed in normal liver. In CRCs, c-Met (p < 0.005) expression was significantly increased compared to normal colonic mucosa, whereas HGF (p < 0.05), Slug (p < 0.01), Zeb1 (p = 0.005), s100a4 (p < 0.05), and vimentin (p < 0.001) expression were significantly downregulated. E-cadherin expression was significantly decreased in CRCs (p < 0.01), and liver metastases (p < 0.005) compared to normal colon. Comparison of expression of EMT markers between CRCs and LMs showed that HGF (p = 0.001), Snail (p < 0.001), Slug (p = 0.026), Zeb1 (p < 0.001), vimentin (p < 0.005), and TGFβ1 (p < 0.005) were all significantly upregulated in LM tissue. Conclusion: EMT markers were significantly increased in LMs compared to CRCs. MACC1 was significantly increased in CRCs, and for the first time shown to be significantly increased in LMs. Snail, TGFβ1, and vimentin, provide the best markers for LM.
Poster No. 3 Post Transcriptional Regulation of Human Heparanase by AU-Rich Element Gil Arvatz 1 , Ofer Nativ2, Neta Ilan1, Israel Vlodavsky1 1 Cancer and Vascular Biology Reasearch Center, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute PJ34 HCl of Technology, Haifa, Israel, 2 Department of Urology, Bnai-Zion Medical Center, Haifa, Israel Heparanase is an endo-β-D-glucuronidase, the predominant enzyme that degrades heparan sulfate side chains of heparan sulfate proteoglycans. Traditionally, heparanase activity was correlated with the metastatic potential of tumor-derived cells, attributed to enhanced cell dissemination as a consequence of heparan sulfate cleavage and remodeling of the extracellular matrix barrier. More recently, heparanase up-regulation was documented in an increasing number of human carcinomas and hematological malignancies.